Poland· PL-100508402

Antixara

A apixaban product containing apixabanum, registered in Poland by Przedsiębiorstwo Farmaceutyczne LEK-AM Sp. z o.o.. The same ATC class is registered in 17 of our 19 countries.

ATC B01AF02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAntixaraATCB01AF02REGISTER NO.PL-100508402PACKS LISTED6CHECKEDSeptember 27, 2026

Where it is registered

Apixaban is registered in 17 of 19 countries.

Countries holding a registration under ATC B01AF02 (apixaban), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose

Apixaban · ATC B01AF02

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of apixaban costs, country by country.

Normalised to the WHO defined daily dose (10 mg), the median price runs from $3.38 in France to $7.97 in Italy — a ×2.4 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Apixaban · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • IT Italy$7.97
  • CH Switzerland$4.70
  • FR France$3.38
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Apixabanum
Manufacturer
Przedsiębiorstwo Farmaceutyczne LEK-AM Sp. z o.o.
Country
Poland (PL)
ATC code
B01AF02
ATC class
Apixaban
Defined daily dose
10 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 6

  • gtin
    05906720530368
  • gtin
    05906720530337
  • gtin
    05906720530344
  • gtin
    05906720530382
  • gtin
    05906720530351
  • gtin
    05906720530375

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

398 interactions on record for apixaban.

Graded by severity as the source publishes them — 133 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Apixaban · interactions on record

398 records

  • 133 severe
  • 224 moderate
  • 2 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe

39 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Apixaban in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All apixaban products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Abatixent, Apixaban +pharma
  • Belgium · Apixaban Ab, Apixaban Eg
  • Bulgaria · Abatixent, Apixaban
  • Cyprus · Abidalo, Apixaban
  • Czechia · Aboxoma, Apixaban
  • Germany · Abidalo, Akkirateron
  • Denmark · Apinovia, Apinovia 5 Mg Film-Coated Tablets
  • Estonia · Abatixent, Aboxoma
  • Spain · Apicassa, Apiclot
  • Finland · Apiclodem, Apixaban
  • France · Apixaban, Apixaban Aet
  • United Kingdom (Northern Ireland) · Apixaban, Apixaban Abdi
  • Greece · Abixatec, Aboxoma
  • Croatia · Abatixent, Abidalo
  • Hungary · Aboxoma, Apixaban
  • Ireland · Apixaban Abdi, Apixaban Aristo
  • Iceland · Apixaban Accord, Apixaban Krka
  • Italy · Apilion, Apixaban Abdi
  • Liechtenstein · Apixaban Accord, Eliquis
  • Lithuania · Abatixent, Aboxoma
  • Luxembourg · Apixaban Eg, Apixaban Ratiopharm
  • Latvia · Abatixent, Aboxoma
  • Malta · Abidalo, Antixara
  • Netherlands · Abatixent, Apilion
  • Norway · Apixaban Accord, Apixaban Axunio
  • Portugal · Apixaban Grindeks, Apixabano Alter
  • Romania · Abatixent, Aboxoma
  • Sweden · Apixaban, Apixaban Axunio
  • Slovenia · Abatixent, Aboxoma
  • Slovakia · Aboxoma, Apixaban

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f79d52db-712e-47ee-99ef-96df1e4e216c
GET /v1/drugs/f79d52db-712e-47ee-99ef-96df1e4e216c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "5 mg",
  "packaging": "05906720530368 ¦ Rp ¦ 168265\n120 tabl.\n05906720530337 ¦ Rp ¦ 168266\n30 tabl.\n05906720530344 ¦ Rp ¦ 168267\n60 tabl.\n05906720530382 ¦ Rp ¦ 168268\n180 tabl.\n05906720530351 ¦ Rp ¦ 168269\n90 tabl.\n05906720530375 ¦ Rp ¦ 168270\n150 tabl.",
  "substance": "Apixabanum 5 mg",
  "common_name": "Apixabanum",
  "pl_product_id": "100508402",
  "pozwolenie_nr": "29672",
  "auth_procedure": "DCP",
  "authorisation_validity": "2031-07-16"
}

See everything about apixaban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.